Last deal

Amount

Grant

Stage

21.10.2022

Date

3

all rounds

$4.13M

Total amount

date founded

Financing round

General

About Company
ATXA is a clinical-stage pharmaceutical company that develops novel small molecule drugs to treat Pulmonary Arterial Hypertension.

Industry

Sector :

Subsector :

Keywords :

Also Known As

ATXA

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

Founded in 2015, ATXA Therapeutics is a spin-out company from University College Dublin that has developed a series of highly selective small molecule drugs to treat a number of disease indications, including PAH, thrombosis/cardiovascular, oncology, and anti-inflammatory. With expertise in cardiovascular and cancer biology, drug discovery, and early development, ATXA is committed to advancing the late-stage development of their novel therapies that display substantial improvements over the existing standard-of-care, addressing critical unmet medical needs for efficacious new therapies to treat PAH. The company's drugs use an alternative approach to achieve improved vasodilation and to reduce the vasoconstrictive potential by antagonizing/inhibiting the action of the prostanoid thromboxane, offering patients new hope and bettering their lives.
Contacts
Legal Names

Legal name

ATXA Therapeutics Limited
Similar Companies
1000
Durata Therapeutics

Durata Therapeutics

Durata Therapeutics is a clinical development stage biopharmaceutical company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

Branford, CT, USA

total rounds

1

total raised

$70M
Verona Pharma

Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company that develops innovative therapies for chronic respiratory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

London, UK

total rounds

7

total raised

$1.51B
PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals

PhaseBio develops drugs for endocrine disorders, cardiovascular disease, and orphan diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Malvern, PA 19355, USA

total rounds

11

total raised

$324.3M
Karyopharm Therapeutics

Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for cancer and other major diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Newton, MA, USA

total rounds

8

total raised

$546.7M

Financials

Funding Rounds
4
3

Number of Funding Rounds

$4.13M

Money Raised

Their latest funding was raised on 21.10.2022. Their latest investor European Innovation Council. Their latest round Grant

Date 
Funding Round 
Investors 
Money Raised 
Lead 
01.10.2018
1
$4.13M
Local Amount - EUR 3.57M
European Innovation Council

European Innovation Council

The EIC pilot supports innovators and entrepreneurs by providing funding, advice, and networking opportunities for cutting-edge innovation.

Sector

Media

Subsector

Media Agencies

Keywords

Consulting

Location

Brussels, Belgium

count Of Investments

1179

count Of Exists

5
European Innovation Council

European Innovation Council

The EIC pilot supports innovators and entrepreneurs by providing funding, advice, and networking opportunities for cutting-edge innovation.

Sector

Media

Subsector

Media Agencies

Keywords

Consulting

Location

Brussels, Belgium

count Of Investments

1179

count Of Exists

5
Co-Investors
Investors
3
1

Number of lead investors

3

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Grant, Venture - Series Unknown
No
Venture - Series Unknown
European Innovation Council

European Innovation Council

The EIC pilot supports innovators and entrepreneurs by providing funding, advice, and networking opportunities for cutting-edge innovation.

Sector

Media

Subsector

Media Agencies

Keywords

Consulting

Location

Brussels, Belgium

count Of Investments

1179

count Of Exists

5
Enterprise Ireland

Enterprise Ireland

Enterprise Ireland is a government agency that funds and develops Irish businesses to achieve strong positions in global markets.

Sector

Industrial Support Services

Subsector

Professional Business Support Services

Keywords

Venture Capital, Government

Location

Dublin, Ireland

count Of Investments

760

count Of Exists

85
Sean McKeown

Sean McKeown

current job

Enterprise Ireland
Enterprise Ireland
EASME - EU Executive Agency for SMEs

EASME - EU Executive Agency for SMEs

EASME manages EU programs for SMEs, environment, energy, and maritime projects.

Sector

Industrial Support Services

Subsector

Professional Business Support Services

Keywords

Energy, Project Management

Location

Brussels, Belgium

count Of Investments

3607

count Of Exists

165

People

Founders
2
Therese Kinsella
Therese Kinsella

Therese Kinsella

Therese Kinsella is Professor of Biochemistry within the School of Biomolecular and Biomedical Sciences, UCD. She is a leading expert in the field of prostanoid biology, focusing on the vasculature and has published extensively in this area in top journals and book chapters. Therese has patent-protected her work, including in the discovery and development of TP antagonists. She has also acted as expert consultant to large pharmaceutical, biotech & life science venture capital funds. In recognition of her contribution to her research field, she has received a number of awards during her professional career including; Royal Irish Academy Medal in Biochemistry (2000); Elected Member Royal Irish Academy (MRIA, 2006); Biochemical Society (IAS) Gold Medal (2008). She has extensive expertise in securing research funding and in grant management and has, for example, held a prestigious WT program grant and several WT project grants. She has secured three successive commercialization-type grants: Enterprise Ireland and Science Foundation Ireland, enabling the drug-discovery/development from target identification; generation and characterization of novel TP antagonists, including ATXA's lead drug, NTP42 ; development and prioritization of target market. Having begun her research career in industry (Guinness), she has a strong appreciation of the underlying processes of product/drug development, including associated challenges.

current job

ATXA Therapeutics
ATXA Therapeutics

organization founded

1

Therese Kinsella

Daniel O' Mahony
Daniel O' Mahony

Daniel O' Mahony

Daniel O’ Mahony has 26 years international experience at a senior level of management in industry and scientific research, ten years of which were at Elan Corporation where he held the positions of VP Technology & Asset Divestment and VP Experimental Biology followed by R&D Director at Taro Pharmaceuticals. He has held academic posts at the Biochemistry Department, University College Cork; the Genetics Department, Trinity College, Dublin; The Weis Research Centre, PA, USA; the Department of Medicine & Experimental Therapeutics, University College Dublin and the Mater Hospital Centre for Cardiovascular Science. He established the very successful Technology Transfer Office at the National University Ireland, Galway in 2005. His skills encompass major aspects of biopharmaceutical and biotechnology industries, technology licensing from university sector and campus company formation. He is a named inventor on 25 patents, author of over 40 publications and presenter and speaker at numerous international conferences. He sits on the board of a number of private companies. He holds a Ph.D in biochemistry and molecular genetics from University College Cork and a business degree in technology management from the Smurfit business school, University College Dublin. He has been a member of Kernel Capital Advisory board since 2002 and since then he has lead over 25 comprehensive due diligence reviews on behalf of the firm. He commenced a full time position with Kernel as a Partner in January 2008.

current job

Seroba Life Sciences
Seroba Life Sciences

organization founded

1

Daniel O' Mahony

Employee Profiles
3
Ivan Coulter

Ivan Coulter

Chief Executive Officer

Daniel O' Mahony

Daniel O' Mahony

Co-Founder

Therese Kinsella

Therese Kinsella

Founder and Chief Scientific Officer

Activity

Recent News
0